Rebound Infections Occur in 20% of Paxlovid Users, According to New Research
COVID-19 has become less of an urgent threat than it was in 2019 largely because of vaccines and growing immunity from natural infections, but antiviral treatments have also changed the course of the disease. The most popular of these is nirmatrelvir-ritonavir, sold under the brand name Paxlovid, which the U.S. Centers for Disease Control and Prevention (CDC) recommends for older people and anyone over age 12 who is at higher risk of COVID-19 complications. But people taking the drug have reported incomplete recovery, or testing positive again after testing negative once they finished the five-day course of the oral medica...
Source: TIME: Health - November 14, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
Pfizer Stock Hits 3-Year Low —Down 50% From 2021 Peak
Excluding a brief early 2020 plunge, Pfizer shares are now trading at their lowest level since 2016. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 13, 2023 Category: Pharmaceuticals Authors: Derek Saul, Forbes Staff Tags: Business /business Money /money Markets /markets Innovation /innovation Healthcare /healthcare Breaking breaking-news Education topline Source Type: news
Pfizer CEO's vaccine message sparks uproar
A message from Pfizer CEO Albert Bourla has brought outrage on social media, with his post receiving more than 3 million views. Bourla's November 9 post on X (formerly Twitter) celebrated the three-year anniversary of Pfizer's COVID-19 vaccine passing safety trials. "Three years ago today, we were…#pfizer #albertbourla #bourla #rileygaines #ryangerritson #stacyphillips #bioweapon #cdc #fda #factcheckorg (Source: Reuters: Health)
Source: Reuters: Health - November 13, 2023 Category: Consumer Health News Source Type: news
Certain COVID-19 Vaccines Linked To Elevated Risk Of Guillain-Barr é Syndrome
Certain COVID-19 Vaccines Linked To Elevated Risk Of Guillain-Barré Syndrome Authored by Ellen Wan via The Epoch Times (emphasis ours), As the vaccination rate continues to rise, an increasing number of side effects are being reported. Research indicates that COVID-19 viral vector-based vaccines…#vaccineslinked #ellenwan #epochtimes #gbs #astrazeneca #scientificreports #gyeonggiprovince #pfizer #moderna #malta (Source: Reuters: Health)
Source: Reuters: Health - November 12, 2023 Category: Consumer Health News Source Type: news
Pfizer's Weight Loss Pill Is a Do-Or-Die Milestone
Pfizer is approaching a do-or-die milestone in the coming weeks, as it prepares to unveil new data on its weight-loss pill. If the drug works well, Pfizer could capture some of the investor enthusiasm that has blasted the share prices of Novo Nordisk and Eli Lilly into the stratosphere this year.#pfizer #novonordisk #elililly (Source: Reuters: Health)
Source: Reuters: Health - November 8, 2023 Category: Consumer Health News Source Type: news
Today
Stock market today: Asian shares mostly slip ahead of China-US meeting, by Yuri Kageyama WeWork seeks bankruptcy protection in stunning fall for a company once valued close to $50 billion, by Wyatte Grantham-Philips More Americans are yanking money from their 401(k) plans to pay the bills, by Matt…#yurikageyama #wework #mattegan #pfizer #relocateworkers #emonreiser #lizyoung #wondergroup #nestle #melissarepkoenergy (Source: Reuters: Health)
Source: Reuters: Health - November 8, 2023 Category: Consumer Health News Source Type: news
Breakingviews - Maersk's woes signal slow-motion industry crash
Container ship "Evelyn Maersk" is loaded during snowfall at a container terminal in a harbour amid the coronavirus disease (COVID-19) pandemic, in Hamburg, Germany, April 6, 2021. REUTERS/Fabian Bimmer Acquire Licensing Rights LONDON, Nov 3 (Reuters Breakingviews) - Shipping giant A.P.…#hamburg #reutersbreakingviews #apmollermaersk #danish #bossvincentclerc #dnbmarkets #clerc #jpmorgan #pamelabarbaglia #pfizer (Source: Reuters: Health)
Source: Reuters: Health - November 5, 2023 Category: Consumer Health News Source Type: news
Contra CATO: COVID-19 Vaccinations Are Not a Free Market Victory
In light of Nobel Prizes being given to two researchers of mRNA covid-19 vaccinations, beltway establishments like that of the Cato Institute have lauded praises onto the decision. To Cato, as evidenced by a blog post by Ian Vásquez, the production of these vaccines was a “victory of…#nobelprizes #catoinstitute #cato #ianvásquez #spanish #vásquez #operationwarpspeed #donaldtrump #pfizer #frédéricbastiats (Source: Reuters: Health)
Source: Reuters: Health - November 4, 2023 Category: Consumer Health News Source Type: news
Pediatric Neurogenic Bladder Cases Are Not Fully Evaluated
FRIDAY, Nov. 3, 2023 -- Pediatric neurogenic bladder (NGB) cases are not fully evaluated in routine clinical practice, according to a study published online Oct. 16 in Advances in Therapy.
Naoko Izumi, from Pfizer Japan in Tokyo, and colleagues... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 3, 2023 Category: Pharmaceuticals Source Type: news
UK Regulator Approves Pfizer's Hair Loss Drug UK Regulator Approves Pfizer's Hair Loss Drug
Britain ' s medicines regulator on Wednesday approved Pfizer ' s drug to treat hair loss caused by an autoimmune disease.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - November 2, 2023 Category: Allergy & Immunology Tags: Dermatology News Alert Source Type: news
There ’s a Shortage of RSV Treatments. Here’s What Doctors Recommend
A recently approved treatment was supposed to protect babies from RSV, but demand is outpacing the supply of the medication.
The U.S. Food and Drug Administration approved nirsevimab, an antibody that sticks to and prevents Respiratory Syncytial Virus from infecting cells, in July. The Centers for Disease Control and Prevention (CDC) then recommended the medication for all babies either born during the RSV season or those up to eight months old entering their first RSV season, which runs from about November to March. RSV can be a dangerous and potentially deadly disease, especially for infants; about 58,000 to 80,...
Source: TIME: Health - November 2, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized healthscienceclimate Source Type: news
Unlike Pfizer, Moderna can meet 2023 COVID forecast, analysts say
Syringes with needles are seen in front of a displayed Moderna logo in this illustration taken, November 27, 2021. REUTERS/Dado Ruvic/Illustration/File Photo Acquire Licensing Rights Nov 1(Reuters) - Moderna (MRNA.O) should hit the lower end of its sales target for this year as it only needs to…#moderna #oppenheimerco #hartajsingh #jefferies #michaelyee #yee #pfizer #rsv #gsk (Source: Reuters: Health)
Source: Reuters: Health - November 1, 2023 Category: Consumer Health News Source Type: news
Pfizer Layoffs Confirmed As Vaccine Manufacturer Drives For Cost Savings
Pfizer is laying off an undisclosed amount of employees after confirming it’s shutting down its New Jersey facility • Two other facilities are closing in North Carolina, with other layoffs in Illinois and Colorado • Pfizer’s share price was flat as the company reported a narrower-than-expected…#pfizer #newjersey #northcarolina #illinois #colorado #pfizerspeapack #noncovid #albertboura #q3 #astrazeneca (Source: Reuters: Health)
Source: Reuters: Health - November 1, 2023 Category: Consumer Health News Source Type: news
Column: How CEOs are threading the needle in talking about Israel and Gaza
Pfizer CEO Albert Bourla is one of many American corporate leaders making statements supporting Israel in the aftermath of the Hamas terror attack. “Disappointing at best, disastrous at worst”: That’s how Anti-Defamation League Chief Executive Jonathan Greenblatt described the response of American…#pfizer #albertbourla #israel #hamas #antidefamationleague #jonathangreenblatt #israeli #yale #adl #workplacepledge (Source: Reuters: Health)
Source: Reuters: Health - November 1, 2023 Category: Consumer Health News Source Type: news
Pfizer quarterly results hit by soft demand for COVID-19 products
Pfizer on Tuesday reported its first quarterly loss since 2019 as demand for its COVID products dwindled. Sales of the company's coronavirus vaccine Comirnaty dropped 70% during the third quarter compared with the same period a year earlier. Sales of its COVID-19 treatment Paxlovid fell 97% from…#pfizer #marcsiegel #albertbourla #abrysvo #elrexfio #seageninc (Source: Reuters: Health)
Source: Reuters: Health - November 1, 2023 Category: Consumer Health News Source Type: news
